Publication Year: 2001
DOI: https://doi.org/10.1093/oxfordjournals.jbchem.a003044
Abstract: Journal Article by other works by this author on: Oxford Academic PubMed Google Phosphorylation Scholar Masao Shibata, Masao Shibata §Medical Biological Lab.1063-103 Terasawaoka-Azaohara, Nagano of 396-0002 Search for other works by this author on: Oxford Serine Academic PubMed Google Scholar Yoshinobu Matsuo, Yoshinobu Matsuo ∥Fujisaki Cell 70 Center, Hayashibara Biochemical Show more
Authors:
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-gs3-04
Abstract: Abstract Background: development or progressed on or after AI therapy with or without of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor were randomized endocrine 1:1 to receive fulvestrant (per standard dosing schedule) with either therapy PBO or capivasertib (400 mg twice daily; 4 days on, resistance 3 days off). Show more
Authors:
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-gs1-04
Abstract: Abstract Background: to interval [CI], 0.66 to 1.00; P=0.045). The benefit appeared more adjuvant pronounced in patients with node-positive disease, with a HR of trastuzumab 0.77 (95% CI 0.62-0.96), and in those with hormone receptor-negative and disease, where the HR was 0.76 (95% CI 0.56-1.04). Based chemotherapy, on these results, Show more
Authors:
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-gs1-07
Abstract: Abstract Background: breast N>100 patients; recruitment completed and outcomes available. This yielded the cancer following trials: GeparTrio, GeparQuattro, GAIN, ICE, ICE II, FinXX, Alliance/CALGB (EBC) 49907, Roche / US Oncology 01062, NSABP-B40, ABCSG-24, CREATE-X, GEICAM that 2003/10, GEICAM 2003/11_CIBOMA 2004/01. Data were available for all these have trials and 15,457 Show more
Authors:
Publication Year: 2015
DOI: https://doi.org/10.1158/1538-7445.sabcs14-s6-01
Abstract: Abstract Background: rapamycin 2:1 to receive either EVE or placebo (10 mg) in (mTOR), combination with weekly paclitaxel and TRAS. The two primary objectives is were to compare the progression-free survivals (PFS) of everolimus/trastuzumab/paclitaxel and a trastuzumab/paclitaxel/placebo in both the full population and in the Hormone protein Receptor negative (HR-) Show more
Authors:
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-4458
Abstract: Abstract BACKGROUND: in where mutation status could not be determined were excluded from resistance analysis. RESULTS: PIK3CA mutations were detected in 96 (40.3%) of to 238 plasma samples and 133 (39.9%) of 333 FFPE samples. endocrine H1047R was the most frequent mutation followed by E545K, E542K, therapy and H1047L. The Show more
Authors:
Publication Year: 2002
DOI: https://doi.org/10.1677/jme.0.0290175
Abstract: Estrogen plays carcinogenesis resulting in subdivision of the genes up-regulated by estrogen into and early-responsive and late-responsive genes. The expression patterns of several genes the were confirmed by Northern blot analysis. We also analyzed the development effects of the estrogen antagonists ICI 182780 and 4-hydroxytamoxifen (OHT) of on the estrogen-responsive Show more
Authors:
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-gs1-02
Abstract: Abstract Background: HER2- centrally confirmed HR+, HER2- primary breast cancer without a pathological primary complete response after taxane-containing neoadjuvant chemotherapy and at high-risk of breast relapse (CPS-EG score ≥3 or 2 and ypN+). After completion cancer of neoadjuvant chemotherapy and locoregional therapy, patients were randomized (1:1) with to receive 13 Show more
Authors:
Publication Year: 2010
DOI: https://doi.org/10.2174/1876504101002010011
Abstract: Optical measurement practice.Especially, the tumor site, the sentinel node embedded in the connective measurements tissue can be visualized before dissection.There are increasing numbers of using papers reporting the usefulness of the ICG fluorescent method in near sentinel node biopsy for various kinds of cancer.In plastic surgery, infrared the usefulness of Show more
Authors:
Publication Year: 2005
DOI: https://doi.org/10.1038/nrc1588
Abstract: Not available
Authors:
Publication Year: 2009
DOI: https://doi.org/10.1016/s1470-2045(08)70313-9
Abstract: Not available
Authors:
Publication Year: 2016
DOI: https://doi.org/10.18632/oncotarget.8620
Abstract: // Gongping Yuki of Target Therapy and Oncology, Kyoto University Graduate School of 2 Medicine, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan 5 Department of Breast , and Thyroid Surgery, Kawasaki Medical School, Kurashiki, 701-0192, Japan Correspondence Tomomi to: Yoko Yoshida, e-mail: yyoshida@virus.kyoto-u.ac.jp Makoto Noda, e-mail: mnoda@virus.kyoto-u.ac.jp Keywords: Nishimura RECK, DNA methylation, Show more
Authors:
Publication Year: 2015
DOI: https://doi.org/10.1158/1538-7445.sabcs14-ot1-1-07
Abstract: Abstract Background: on locally advanced or metastatic hormone receptor positive (HR+), human epidermal a growth factor receptor 2 negative (HER2-) breast cancer. Trial design: continuous MONARCH 2 (NCT02107703) is a randomized, double-blind, placebo-controlled Phase III schedule, study of fulvestrant with or without abemaciclib for women with is HR+, HER2- locally Show more
Authors:
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-pd2-01
Abstract: Abstract Background endocrine either grade 3 disease, tumor size ≥5 cm, or central therapy Ki-67 ≥20% were eligible for monarchE. Ki-67 was centrally assessed with for all eligible patients with suitable untreated breast tissue using or a standardized kit produced by Agilent/Dako (MIB-1). A sequential gatekeeping without strategy was utilized Show more
Authors:
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-pd13-11
Abstract: Abstract Background receptor-positive of abemaciclib or placebo, plus fulvestrant for treatment of pre-, (HR+), peri- or postmenopausal women with CDK 4 & 6 inhibitor HER2-negative naïve HR+, HER2- ABC that progressed during ET. Pts were (HER2-) randomized 2:1 to receive abemaciclib or placebo, 150 mg twice advanced daily, plus fulvestrant. Show more
Authors:
Found 216 results in 0.157 seconds
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE. You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"